UNSPSC 51161704: Colfosceril

This classification denotes an agent affecting respiratory system with the molecular formula C40H80NO8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 319X2NFW0A, chemically known as 3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxohexadecyl)oxy)-, inner salt, 4-oxide but generally known as colfosceril palmitate, which bears US NIH Compound Identifier 6138.

UNSPSC 51161704 Colfosceril is a Commodity code that in recent state and local solicitations covers pharmaceutical products and pharmacy services procurement — though the opportunities posted under this code diverge significantly from colfosceril (a synthetic lung surfactant) specifically. Seminole County, Florida solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually through IFB 60459723LAS, while Hall County, Georgia issued RFQ/P #47-010 to procure comprehensive on-site pharmacy services for approximately 3,005 eligible individuals enrolled in the county's group health insurance plans, including stocking and dispensing of 25 medications across multiple therapeutic categories. The scope mix reflects county-level public health and employee health benefit administration rather than colfosceril procurement specifically. Issuing bodies under this code include county governments operating community health initiatives and employee health clinics; school districts and state departments do not appear in the recent record.

Seminole County, Florida and Hall County, Georgia are the two jurisdictions with posted activity. Seminole County's IFB 60459723LAS, posted June 30, 2026 with a July 26, 2023 due date (note: the source contains inconsistent dates), required quarterly deliveries to the Seminole County Community Health Building in Sanford and included FEMA compliance requirements. Hall County's RFQ/P #47-010, posted May 4, 2026 with a June 4, 2026 response deadline, employed an 80/20 technical-to-cost scoring structure, required sealed cost proposals, and called for a January 1, 2027 contract start with four one-year renewal options. Both opportunities required E-Verify compliance and standard insurance documentation; neither specified set-asides for disadvantaged enterprises. The code shows sparse recent activity and exhibits a significant mismatch between its nominal commodity (colfosceril) and the pharmaceutical services and harm-reduction products actually being procured.